Efficacy of low dose thalidomide in multiple myeloma

Electronic Journal of Oncology

Volumn , Issue 1, 2000, Pages 1-8

  Durie, Brian G M ^a   Stepan, Daniel E ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; ERYTHROPOIETIN; GLUCOCORTICOID; M PROTEIN; NITROSOUREA; THALIDOMIDE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; FEMALE; HUMAN; LOW DRUG DOSE; MALE; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PSYCHOMOTOR DISORDER; SEDATION; SOMNOLENCE; STEM CELL TRANSPLANTATION; TREMOR;

EID: 0001955290     PISSN: 12928933     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaisssie E, Wilson C, Dhodapkar M, Zeldis J, and Barlogie B: Antitumor activity of thalidoimide in refractory multiple myeloma. New Engl J Med 341:1565-1572, 1999.
2. Quilitz R: Thalidomide in oncology: The peril and the promise. Cancer Control 6:483-495, 1999.
3. Gahrton G and Durie BGM: Multiple Myeloma, Chapter 11 pp108-129. Arnold Publishing New York, NY 1996.
4. Celgene Corporation. Warren NJ: Compassionate use experience: Dose response., 1996.
5. Durie BGM, Dixon D, Carter S, Stephens R, Rivkin S, Bonnet J, Salmon S, Dabich L, Files J, and Costanzi JJ: Improved survival duration with combination chemotherapy induction for multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol 4:1227-1237, 1986.
6. Durie BGM: Staging and kinetics of multiple myeloma. Clinics in Haematology 11:3-18, 1982.
7. Durie BGM, D'Agnelo A, and Waxman AD: Whole body FDG/PET scanning in multiple myeloma. J Nuc Med 40: (5) Abstract#246 May, 1999.
8. D'Amato R, Loughnan MS, Flynn E, and Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 91:4082-4085, 1994.
9. Jones Ph and Harris AL: The current status of clinical trials in anti-angiogenesis. PPO Update Principles and Practice of Oncology 14:1-7, 2000.
10. Fine HA, William DF, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Bvlack PM, Kaplan R, Pluda J, and Yung WKA: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18:708-715, 2000.
11. Rajkumar SV, Fonseca R, Witzig TE, Gertz MA and Greipp PR: Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia 13:469-472, 1999.
12. Sampaio EP, Kaplan G, Miranda A, Nery JAC, Miguel Cp, Viana SM, and Sarno EN: The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infectious Diseases 168:408-414, 1993.
13. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva K, Yurdakul S, Zwingenberger K, and Yazici H: Thalidomide in the treatment of the mucocutaneous lesions of Behcet Syndrome. J Intern Med 128:443-450, 1998.
14. Jacobsson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, Fox L, Chernoff M, Wu AW, MacPhail LA, Vasquez GJ, and Wohl DA: Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. New England Journal of Medicine 336:1487-1493, 1997.
15. Tsenova L, Sokol K, Freedman VH, and Kaplan G: A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis - associated death. J Infect Diseas 177:1563-1572, 1998.
16. Atra E and Sato EI: Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 11:487-493, 1993.
17. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, and Kaplan G: Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J Exp Med 173:699-703, 1991.
18. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, and Kaplan G: Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med 177;1675-1680, 1993.
19. Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Flockhart DA, Trinchieri G, and Karp CL: Inhibition of IL-12 production by thalidomide. J Immun 159:5157-5161, 1997.
20. Kubin M, Chow JM, and Trinchieri G: Differential regulation of interleukin-12 (IL-12), tumor necrosis factor α, and Il-1β production in human myeloid leukemia cell lines and peripheral blood mononuclear cells. Blood 83:1847-1855, 1994.
21. D'Andrea A, Ma X, Aste-Amezaga, M, Paganin C and Trinchieri G: Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor a production. J Exp Med 181;537-546, 1995.
22. Clerici M, Lucey DR, Berzofsky JA, Pinto LA, Wynn TA, Blatt SP, Dolan MJ, Hendrix CW, Wolf SF, and Shearer GM: Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 262:1721-1724, 1993.
23. Makonkawkeyoon S, Limson-Pobre RNR, Moreira AL, Schauf V, and Kaplan G: Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci 90:5974-5978, 1993.
24. Klein B and Bataille. Cytokines network in human multiple myeloma.. Hem Onc Clin No Am 6:273-284, 1992.
25. Carter A, Merchav S, Silvian-Draxler I and Tatarsky I: The role of interleukin-1 and tumour necrosis factor-α in human multiple myeloma. Brit J Haem 74:424-431, 1990.
26. Bataille R, Manolagas SC and Berenson JR: Pathogenesis and management of bone lesions in multiple myeloma. Hem Oncol Clin No Am 11:349-361, 1997.
27. Smith CA, Farrah T, and Goodwin RG: The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76:959-962, 1994.
28. Sen R and Baltimore D: Inducibility of k immunoglobulin enhancer-binding protein NF-κB by a posttranslation mechanism. Cell 47:921-928, 1986.
29. Lichtenstein M, Keini G, Cedar H, and Bergman Y: B cell-specific demethylation: a novel role for the intronic k chain enhancer sequence. Cell 76:913-923, 1994.
30. Kirillov A, Kistler B, Mostoslavsky R, Cedar H, Wirth T, and Bergman Y: A role for nuclear NF-κBin B-cell specific demethylation of the Igκ locus. Nature Genetics 13:435-441, 1996.
31. Darnay BG, Ni J, Moore PA, and Aggarwal BB: Activation of NF-κB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-κB-inducing kinase. J Biol Chem 274:7724-7731, 1999.
32. Wong BR, Besser D, Kim N, Arron JR, Vologodskaia M, Hanafusa H, and Choi Y: TRANCE, a TNF family member, activates Aκt/PKB through a signaling complex involving TRAF6 and c-Src. Molecular Cell 4:1041-1049, 1999.
33. Baeuerle PA and Baltimore D: NF-κB: Ten years after. Cell 87:13-20, 1996.
34. Ghosh S, May MJ, and Kopp EB: NF-κB and REL proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16:225-260, 1998.
35. Abu-Amer Y and Tondravi MM: NF-κB and bone: the breaking point. Nature Medicine 3:1189-1196, 1997.
36. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A and Bravo R: Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nature Medicine 3:1285-1289, 1997.
37. Moore RJ, Owens DM, Stamp G, Arnott FB, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M, Kollias G and Balkwill F: Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nature Medicine 5:828-831, 1999.
38. Wilson AG, Symons JA, McDowell TL, McDevitt HO, and Duff GW: Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci 94:3195-3199, 1997.
39. Jacob CO, Froneck Z, Lewis GD, Koo M, Hansen JA, and McDevitt HO: Heritable major histocompatibility complex class II-associated difference in production of tumor necrosis factor α: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci 87:1233-1237, 1990.
40. Seki N, Yamaguchi K, Yamada A, Kamizono S, Sugita S, Taguchi C, Matsuoka M, Matsumoto H, Nishizaka S, Itoh K, and Mochizuki M: Polymorphism of the 5-Flanking region of the tumor necrosis factor (TNF)-α gene and susceptibility to human T-cell lymphotropic virus type I (HTLV-I) uveitis. J Infec Dis 180:880-883, 1999.
41. Weber DM, Gavino M, Delasalle K, Rankin K, Giralt S, and Alexanian R. Thalidomide alone or with dexamethasone for multiple myeloma. Blood 94:604a Abstract #2686 1999.